An Open-Label, Dose-Finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 [motesanib] With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclitaxel in the Treatment of Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC).
Latest Information Update: 29 Mar 2016
At a glance
- Drugs Motesanib (Primary) ; Carboplatin; Paclitaxel; Panitumumab
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Amgen
- 21 Mar 2014 The study design has been changed from single group assignment to parallel group assignment and primary endpoint has been changed from safety and pharmacokinetics to pharmacokinetics only as reported by ClinicalTrials.gov record.
- 21 Mar 2014 The study design has been changed from single group assignment to parallel group assignment and primary endpoint has been changed from safety and pharmacokinetics to pharmacokinetics only as reported by ClinicalTrials.gov record.
- 25 Aug 2009 Actual end date (Mar 2007) and actual number of patients (51) added as reported by ClinicalTrials.gov.